Skip to main content

BIOMARKAPD (Biomarker Optimisation in AD & PD).

Alzheimer’s and Parkinson’s diseases (AD and PD) are the two most common neurodegenerative conditions. They cause major costs for society and suffering and death for millions of patients around the globe. In Europe, more than 8 million individuals have AD or PD. Current treatments are symptomatic but do not stop the underlying disease process. Using biomarkers, we can detect biochemical changes that show when neurons start to die. There are also biochemical tests for brain changes that are specific to AD and PD.

NeuroSKILL - Neuroimaging Skills in Dementia.

Project Aim(s): 

The project has various complementary aims: (a) research on normal ageing and Alzheimer's disease using MRI-based methods, (b) develop training programmes in neuroimaging in dementia, (c) develop greater understanding of the use of neuroimaging by clinicians for diagnosis of Alzheimer's disease, (d) technology transfer between centres.

Investigating Ageing-related Deficits in Cognition: A Combined Multimodal fMRI-DTI.

Project Aim(s): The objective is the assessment of the impact of alterations of white matter tract integrity on effective connectivity in the neural network underpinning working memory.  Using brain imaging data it will examine the associations between brain structure and function in young and older healthy participants and how normal ageing alters the relationship between structure and function.

©2024 Dementia Research Network Ireland. Follow us on Twitter: @DRNIre